FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3190837124> ?p ?o ?g. }

• W3190837124 endingPage "S220" @default.
• W3190837124 startingPage "S220" @default.
• W3190837124 abstract "Napabucasin is a first-in-class, investigational, orally-administered, reactive oxygen species generator bioactivated by the intracellular antioxidant NAD(P)H:quinone oxidoreductase 1. Phosphorylated signal transducer and activator of transcription 3 (pSTAT3) is a transcription factor hypothesized to predict a treatment effect from napabucasin in metastatic colorectal cancer (mCRC). We present the final efficacy analysis of CanStem303C in patients with previously treated mCRC. CanStem303C (NCT02753127) was a multi-center, open-label, randomized study of patients aged ≥18 years with histologically confirmed mCRC who failed first-line fluoropyrimidine plus oxaliplatin ± bevacizumab treatment. Patients were randomized 1:1 to FOLFIRI + napabucasin 240 mg oral, twice daily (napabucasin) vs FOLFIRI (control). Bevacizumab could be used in either arm at investigator discretion. Randomization was stratified by geographical region, time to progression from start of first-line therapy, RAS mutation status, bevacizumab as part of protocol treatment, and primary tumor location. Primary endpoints were overall survival (OS) in the general study population (GSP; all randomized patients) and the pSTAT3+ (biomarker-positive [BM+]) population. Key secondary endpoints included progression-free survival (PFS), disease control rate (DCR), and objective response rate (ORR) in the GSP and BM+ population. BM+ status was identified via pSTAT3 immunohistochemistry D3A7 Clinical Trial Assay (Agilent Technologies, Inc.) to detect pSTAT3 protein in cut tissue sections. For the GSP, the study was designed to have 90% power at 1-sided α of 0.025 to detect a 20% reduction in risk of death (hazard ratio [HR] for napabucasin vs control=0.80). For the BM+ population, the study was designed to have ∼88% nominal power at 1-sided α of 0.025 to detect a 30% reduction in risk of death (HR=0.70). OS, summarized using the Kaplan–Meier method, was compared between treatment arms using a stratified (GSP; adjusted for actual stratification) and unstratified (BM+ population) log-rank test. The GSP included 1253 pts (n=624 napabucasin; 629 control); mean (standard deviation) age was 60.1 (11.17) and 59.6 (11.14) years respectively; and 44% of pts were BM+ (n=275 napabucasin; n=272 control). In the GSP, median (m) OS was 14.3 months (napabucasin) vs 13.8 months (control) (HR=0.976, 1-sided p=0.3629). In the BM+ population, mOS was 13.2 months (napabucasin) vs 12.1 months (control) (HR=0.969, 1-sided p=0.3782). PFS, DCR, and ORR were similar between treatment arms in the GSP and BM+ population. Any-grade treatment-emergent adverse events (TEAEs) were reported in 99.5% and 98.7% of patients in the GSP (napabucasin; control), the most common (≥30% of patients) of which were diarrhea (84.6%, 53.9%), nausea (60.5%, 50.5%), vomiting (41.2%, 29.3%), and abdominal pain (41.0%, 25.2%). Grade ≥3 TEAEs were reported in 73.8% and 66.7% of patients in the GSP (napabucasin; control), the most common (≥10% of patients) of which were diarrhea (21.2%, 7.0%), decreased neutrophil count (13.7%, 19.2%), and neutropenia (13.3%, 15.2%). The safety profile in the BM+ population was consistent with that in the GSP. For patients with previously treated mCRC, the addition of napabucasin to FOLFIRI ± bevacizumab did not improve OS, PFS, DCR, or ORR in either the GSP or the BM+ population. TEAEs were consistent with previously published data." @default.
• W3190837124 created "2021-08-16" @default.
• W3190837124 creator A5002562596 @default.
• W3190837124 creator A5012034272 @default.
• W3190837124 creator A5015509025 @default.
• W3190837124 creator A5023840587 @default.
• W3190837124 creator A5024180743 @default.
• W3190837124 creator A5025322322 @default.
• W3190837124 creator A5025634287 @default.
• W3190837124 creator A5028472820 @default.
• W3190837124 creator A5029706475 @default.
• W3190837124 creator A5036340946 @default.
• W3190837124 creator A5057458005 @default.
• W3190837124 creator A5059147051 @default.
• W3190837124 creator A5061200817 @default.
• W3190837124 creator A5062748030 @default.
• W3190837124 creator A5071445293 @default.
• W3190837124 creator A5078465312 @default.
• W3190837124 creator A5080423970 @default.
• W3190837124 creator A5089202777 @default.
• W3190837124 creator A5090645179 @default.
• W3190837124 creator A5091727687 @default.
• W3190837124 date "2021-07-01" @default.
• W3190837124 modified "2023-10-02" @default.
• W3190837124 title "O-7 FOLFIRI ± napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C study" @default.
• W3190837124 doi "https://doi.org/10.1016/j.annonc.2021.05.011" @default.
• W3190837124 hasPublicationYear "2021" @default.
• W3190837124 type Work @default.
• W3190837124 sameAs 3190837124 @default.
• W3190837124 citedByCount "2" @default.
• W3190837124 countsByYear W31908371242022 @default.
• W3190837124 countsByYear W31908371242023 @default.
• W3190837124 crossrefType "journal-article" @default.
• W3190837124 hasAuthorship W3190837124A5002562596 @default.
• W3190837124 hasAuthorship W3190837124A5012034272 @default.
• W3190837124 hasAuthorship W3190837124A5015509025 @default.
• W3190837124 hasAuthorship W3190837124A5023840587 @default.
• W3190837124 hasAuthorship W3190837124A5024180743 @default.
• W3190837124 hasAuthorship W3190837124A5025322322 @default.
• W3190837124 hasAuthorship W3190837124A5025634287 @default.
• W3190837124 hasAuthorship W3190837124A5028472820 @default.
• W3190837124 hasAuthorship W3190837124A5029706475 @default.
• W3190837124 hasAuthorship W3190837124A5036340946 @default.
• W3190837124 hasAuthorship W3190837124A5057458005 @default.
• W3190837124 hasAuthorship W3190837124A5059147051 @default.
• W3190837124 hasAuthorship W3190837124A5061200817 @default.
• W3190837124 hasAuthorship W3190837124A5062748030 @default.
• W3190837124 hasAuthorship W3190837124A5071445293 @default.
• W3190837124 hasAuthorship W3190837124A5078465312 @default.
• W3190837124 hasAuthorship W3190837124A5080423970 @default.
• W3190837124 hasAuthorship W3190837124A5089202777 @default.
• W3190837124 hasAuthorship W3190837124A5090645179 @default.
• W3190837124 hasAuthorship W3190837124A5091727687 @default.
• W3190837124 hasConcept C121608353 @default.
• W3190837124 hasConcept C126322002 @default.
• W3190837124 hasConcept C143998085 @default.
• W3190837124 hasConcept C207103383 @default.
• W3190837124 hasConcept C2776694085 @default.
• W3190837124 hasConcept C2776705615 @default.
• W3190837124 hasConcept C2777802072 @default.
• W3190837124 hasConcept C2780962732 @default.
• W3190837124 hasConcept C2908647359 @default.
• W3190837124 hasConcept C44249647 @default.
• W3190837124 hasConcept C526805850 @default.
• W3190837124 hasConcept C71924100 @default.
• W3190837124 hasConcept C98274493 @default.
• W3190837124 hasConcept C99454951 @default.
• W3190837124 hasConceptScore W3190837124C121608353 @default.
• W3190837124 hasConceptScore W3190837124C126322002 @default.
• W3190837124 hasConceptScore W3190837124C143998085 @default.
• W3190837124 hasConceptScore W3190837124C207103383 @default.
• W3190837124 hasConceptScore W3190837124C2776694085 @default.
• W3190837124 hasConceptScore W3190837124C2776705615 @default.
• W3190837124 hasConceptScore W3190837124C2777802072 @default.
• W3190837124 hasConceptScore W3190837124C2780962732 @default.
• W3190837124 hasConceptScore W3190837124C2908647359 @default.
• W3190837124 hasConceptScore W3190837124C44249647 @default.
• W3190837124 hasConceptScore W3190837124C526805850 @default.
• W3190837124 hasConceptScore W3190837124C71924100 @default.
• W3190837124 hasConceptScore W3190837124C98274493 @default.
• W3190837124 hasConceptScore W3190837124C99454951 @default.
• W3190837124 hasLocation W31908371241 @default.
• W3190837124 hasOpenAccess W3190837124 @default.
• W3190837124 hasPrimaryLocation W31908371241 @default.
• W3190837124 hasRelatedWork W2010928484 @default.
• W3190837124 hasRelatedWork W2014795358 @default.
• W3190837124 hasRelatedWork W2098707609 @default.
• W3190837124 hasRelatedWork W2316610093 @default.
• W3190837124 hasRelatedWork W2333251263 @default.
• W3190837124 hasRelatedWork W2590977625 @default.
• W3190837124 hasRelatedWork W2591743724 @default.
• W3190837124 hasRelatedWork W2617055067 @default.
• W3190837124 hasRelatedWork W2939662662 @default.
• W3190837124 hasRelatedWork W3095986263 @default.
• W3190837124 hasVolume "32" @default.
• W3190837124 isParatext "false" @default.
• W3190837124 isRetracted "false" @default.
• W3190837124 magId "3190837124" @default.

• next